Immobilized Mouse VEGF-A Protein, His Tag at 2 μg/mL (100 μL/well) can bind Recombinant Mouse VEGFR2 (C-Fc) with EC50 of 10-13 ng/ml.
Product Details
Product Details
Product Specification
Species | Mouse |
Synonyms | VEGF164, Vascular permeability factor (VPF), VEGF-1, VEGF164 |
Accession | Q00731-2 |
Amino Acid Sequence | Protein sequence (Q00731-2, Ala27-Arg190, with N-His tag) APTTEGEQKSHEVIKFMDVYQRSYCRPIETLVDIFQEYPDEIEYIFKPSCVPLMRCAGCCNDEALECVPTSESNITMQIMRIKPHQSQHIGEMSFLQHSRCECRPKKDRTKPENHCEPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR |
Expression System | HEK293 |
Molecular Weight | Predicted MW: 21 kDa Observed MW: 25-30 kDa |
Purity | >95% by SDS-PAGE |
Endotoxin | <1EU/μg |
Conjugation | Unconjugated |
Tag | with N-His tag |
Physical Appearance | Lyophilized powder |
Storage Buffer | Lyophilized from a 0.2 μm filtered solution of 0.2M PBS, pH7.4 with 3% trehalose. |
Reconstitution | Reconstitute no more than 1 mg/mL according to the size in deionized water after rapid centrifugation. |
Stability & Storage | 12 months from date of receipt, -20 to -70 °C as supplied. |
Background
VEGFA is a key signaling protein that stimulates angiogenesis (blood vessel formation) and vascular permeability. Produced by various cell types, it binds to receptors VEGFR-1 and VEGFR-2, promoting endothelial cell proliferation, migration, and survival. Overexpressed in tumors, VEGFA supports cancer growth and metastasis by enhancing blood supply. It is a major target in anti-angiogenic cancer therapies, with drugs like bevacizumab (Avastin) blocking its activity. VEGFA also plays critical roles in wound healing and inflammatory diseases.
Picture
Picture
Bioactivity
SDS-PAGE
2μg(R: reducing conditions; NR: non-reducing conditions)
